VIR - the fundamental play
There is something that market is wrong about. The VIR and its blockbuster drug. This drug earns $1-1.5B per Q.
+ they are clinical stage company with Huuge innovative pipeline in HBV and HIV - treatments and VACCINES!
And market prices them like @#$! while they will earn around their own 1x market cap in 2022 and will sit with so much cash, that the current market cap of a company is HUGE misspricing.
+ they are clinical stage company with Huuge innovative pipeline in HBV and HIV - treatments and VACCINES!
And market prices them like @#$! while they will earn around their own 1x market cap in 2022 and will sit with so much cash, that the current market cap of a company is HUGE misspricing.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.